VRTX Financial Facts
Collaborative revenues: 259KTotal costs and expenses: 432.51M
See Full Income Statement
Cash and cash equivalents: 719.69M
Total assets: 2.61B
See Full Balance Sheet
Vertex Pharmaceuticals Incorporated (VRTX) Earnings
|
Expand Research on VRTX
| Next EPS Date | 8/4/26 *Est. | EPS Growth Rate | -100.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +1.3% | Revenue Growth Rate | -100.0% *Last Qtr. |
| Average % Move 1-Wk after EPS | -8.2% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
5/6/26  |
Q126 | N/A | $4.41 | N/A | N/A | $3.07B | = | N/A | N/A | ||
| 2/12/26 | Q425 | $5.03 | $5.08 | -$0.05 | $3.19B | $3.18B | = |  | | Details | |
| 11/3/25 | Q325 | $4.80 | $4.57 | +$0.23 | $3.08B | $3.05B | = | | | Details | |
| 8/4/25 | Q225 | $4.52 | $4.27 | +$0.25 | $2.96B | $2.91B | = | | | Details | |
| 5/5/25 | Q125 | $4.06 | $4.26 | -$0.20 | $2.77B | $2.86B | = | | | Details | |
| 2/10/25 | Q424 | $3.98 | $4.02 | -$0.04 | $2.91B | $2.79B | = | | | Details | |
| 11/4/24 | Q324 | $4.38 | $4.08 | +$0.30 | $2.77B | $2.69B | = | | | Details | |
| 8/1/24 | Q224 | -$12.83 | -$11.70 | -$1.13 | $2.65B | $2.66B | = | | | Details |
